

KEYWORD INDEX, VOLUME 46

- A-3309, 143, 150
 A-803467, 22
 A-887826, 23
 aberrant capsids, 285, 289, 293
 accumulation, 12, 253, 290, 293, 419–420, 422, 424, 441, 460, 464, 479, 487, 494
 ACH-806, 268
 ACH-1095, 268
acinetobacter baumannii, 246
 ACPT-1, 5
 ADC-1004, 175
 affinity, 4, 6, 47, 73, 90–91, 97, 120, 122–123, 126–131, 164, 175, 198, 216, 219–221, 232, 252, 254, 258, 268–269, 275, 288, 302, 305–306, 308–309, 311, 314–315, 321, 324–326, 329, 358, 398, 436, 448, 452, 454, 474, 494
 agonist, 4, 20, 60, 70, 91, 136, 166, 198, 223, 302, 322, 376, 411, 442
 AHR, 321–326
 aldosterone, 90–92, 94–95, 98–100
 aldosterone escape, 92
 ALE-0540, 25, 226
 allergic asthma, 120–121, 330–331
 allergic rhinitis, 120–121, 129, 443, 450
 allodynia, 27, 61
 allosteric, 7–12, 178, 269, 302–303, 310, 314, 328, 490
 alvimopan, 144
 Alzheimer's disease, 341, 375
 AM156, 121, 129
 AM432, 129
 AMG-853, 126–127
 aminoglycosides, 247–248, 375
 AMN082, 12, 14
 amphiphilic, 257, 420–423, 425, 427
 analgesic, 20–21, 28–30, 56, 63, 144, 389, 443, 495–496
 anaphylatoxin, 171–172
 androgen receptor, 89
 anguizole, 269
 antagomir, 361
 antagonist, 6, 25, 56, 90, 120, 142, 172, 214, 303, 325, 426, 438
 antibodies, 25, 30, 158–160, 164, 171–175, 182–183, 217, 223, 293, 358, 436, 440, 459–460, 462, 468
 anti-CD3 antibody, 164
 anti-infective, 303, 412
 antimitotic agent, 228
 antivirals, 197, 264–266, 270–271, 275–276, 283–294, 346, 414, 471–473, 477–480
 AP-80978, 270
 apoptosome, 212
 AR-872, 27
 AR00457470, 27
 arbidol, 266
 ARC1905, 181
 argonaute, 353, 357–358
 ASP-1941, 107–108
 association rate, 303–306
 asthma, 120–121, 178, 330–331, 342, 449
 asynchrony, 48
 AT-406, 221, 223
 atazanavir, 414
 atopic dermatitis, 120, 122
 autoimmunity, 155–167
 AZD 1981, 121
 AZD7295, 271
 azimilide, 54
 aztreonam, 389, 436, 455

 BDD-10103, 412–413
 benzodiazepine, 287, 310–311, 412
 beta-barrel transporter, 258
 beta lactams, 248–251, 259, 453–454
 BG37, 69
 BII10773, 108, 112
 bile acid, 69–85
 bile acid receptor, 69–85
 binding kinetics, 302, 304–305, 307, 314–315
 biochemical efficiency, 304, 308–310
 biologics, 34, 164, 387
 BIT-225, 267
 bivalent, 215–219, 221–223
 blood pressure lowering, 92, 100
 Bmal1, 35–36
 BMS-317180, 146
 BMS-790052, 270
 brain availability, 38, 49
 breast cancer, 192, 194, 197–198, 200, 205, 227–240, 435–436, 461, 466

 C5a receptor, 171–183, 464
 CA_{CTD}, 285, 288–289
 CAD, 426–428

- calcineurin, 339–340, 345–346
calcium channel blockers, 94, 438–439, 492
calmegin, 339
calnexin, 339
calreticulin, 339
canagliflozin, 107–109
cancer, 26, 146, 190, 220, 228, 313, 339, 358, 394, 434
CA_{NTD}, 285–289
capsid assembly inhibitors, 284–292, 294
carboxylic acid, 13, 123, 125, 130–131, 162, 237, 407, 445, 450
CARD. *See* caspaserecruitment domain (CARD)
cardiomyocytes, 374, 377, 379
C5a Receptor (C5aR), 171–183
carrageenan inflammatory pain model, 61
casein kinase (CK) 1, 35
caspase, 212, 342
caspase-3, 212–214, 216, 219, 221
caspase-8, 196, 216
caspase-9, 212–214
caspaserecruitment domain (CARD), 213, 218
CCR6, 161
CCX168, 180–182
CD88, 173
CD147, 339
CD4⁺ T cells, 162, 164, 327–329
cell free system, 221
cell infiltration, 174
CEP-751, 26
ceragenins, 256–257
C-glucoside, 106–109
CH-223191, 162, 325
cheminformatics, 391, 396
chemotaxis, 120, 123, 172, 174–178, 180–181, 339
chemotaxis inhibitory protein of *S. aureus* (CHIPS), 175
CHIPS. *See* Chemotaxis inhibitory protein of *S. aureus* (CHIPS)
cholecystokinin (CCK), 142, 149–150
circadian rhythms (CRs), 33–34, 37, 48–49
cisapride, 137
CK1-7, 40
C5L2, 175, 177, 180
class C GPCR, 4
classical pathway, 172
clemizole, 268
Clinical and Translational Science Award (CTSA) Pharmaceutical Assets Portal, 392, 398
clock, 34–37, 48, 321
clotrimazole, 203–204
c-Myc, 194–196, 200, 370–371
CNS MPO desirability, 38–40
colitis, 160–161, 165–166, 174, 330
collaborative networks, 386, 392–393, 398
competitive, 12, 38, 98, 100, 177, 307–308, 312, 343, 414, 443, 467, 481, 490
complement, 57, 171–173, 183, 194, 232, 276, 353, 361–362, 370, 375, 377, 464
cortisol, 90, 91, 341
CP-447, 697, 179
CP-690550, 160–161
CRTh2 receptor, 126
cryptochrome (Cry), 35–36
CsA. *See* Cyclosporine A (CsA)
CSG-452, 107, 108
CTLA4, 164–166
CTP-347, 413–414
CTP-518, 414
cyclooxygenase, 119, 394, 410, 443
cyclophilin, 286, 339–340, 342–346
cyclosporine A (CsA), 158, 339–341, 343, 345–346
cytochrome P450 (CYP), 77, 93, 178, 320, 322, 405
cytokeratin-18, 222

D4476, 40
danio rerio, 390
dapagliflozin, 107–113
database mining, 392, 398
DEBIO-025, 345–346
delavirdine, 396
dendritic cells (DCs), 156, 161, 326–327, 331–332
15-Deoxyspergualin, 202–203
deuterium, 403–415
dexloxiglumide, 142, 150
diabetes, 70, 84, 100, 103–113, 164, 203, 331, 359, 375, 439, 446–448, 491
diabetic nephropathy, 70, 90, 93, 98, 100
DIABLO, 212
3,3-diaryl oxindoles, 204–205
dicer, 353
differentiation, 26, 156–160, 162–163, 166, 189, 327–328, 371–373, 376, 379, 394, 445, 474, 483
digoxin, 162
dihydropyridines (DHP), 94–97
16,16-dimethylprostaglandin E2, 376

- dioxin, 321–333
 dioxin response element (DRE), 322–323, 326
 disease in a dish, 370
 dissociation rate, 303–307, 314
 diurnal, 48
 DNMT1 inhibitors, 165
 DPP-IV, 425
 DP receptor, 126
 DP2 receptor, 120
 drosha, 352–353
 drug induced phospholipidosis (PLD), 419–428
 drug repositioning, 385–399
 drug repurposing, 386–387, 397
 duloxetine, 389, 443
- E7389, 228, 466
 4EBP-1, 193, 198, 205
 ectinascidin 743, 395
 eculizumab, 172, 182–183
 EGF receptor, 309
 4EGI-1, 195–196
 EGT1442, 109–110
 eIF2. *See* eukaryotic initiation factor 2 (eIF2)
 eIF2 α . *See* eukaryotic initiation factor 2 α (eIF2 α)
 eIF4A. *See* eukaryotic initiation factor 4A (eIF4A)
 eIF4E. *See* eukaryotic initiation factor 4E (eIF4E)
 eIF4F. *See* eukaryotic initiation factor (eIF4F)
 eIF4G. *See* eukaryotic initiation factor 4 gamma (eIF4G)
 E3 ligase, 213, 217–218
 eltrombopag, 376
 enoxacin, 360
 enoyl reductase of mycobacterium tuberculosis (InhA), 314–315
 enzymes, 20, 28–29, 37, 40, 42–45, 47, 91, 179, 247, 250, 252–253, 263–264, 276, 284, 302, 304, 307–309, 322, 327, 338, 339, 342, 360, 391, 395, 405–406, 408, 434, 441, 454, 480–481
 eplerenone, 90, 92–93, 95, 97, 99–100
 ER-086526, 228
 eribulin, 227–240, 435, 465–467
 erythralgia, 21
 erythromycin, 141
 ESKAPE, 246
 eukaryotic initiation factor (eIF4F), 191–193, 196, 200–201
 eukaryotic initiation factor 2 (eIF2), 190–193
 eukaryotic initiation factor 2 α (eIF2 α), 202–205
 eukaryotic initiation factor 4A (eIF4A), 191–193, 199–202
 eukaryotic initiation factor 4E (eIF4E), 191–201
 eukaryotic initiation factor 4 gamma (eIF4G), 191–196, 198–199
 EX-1314, 140
 experimental autoimmune encephalomyelitis (EAE), 158, 161–163, 329, 469
 exportin, 352–353
- FAAH. *See* Fatty acid amide hydrolase (FAAH)
 farnesoid X receptor (FXR), 69–75, 82–84
 fatty acid amide hydrolase (FAAH), 20, 28–30
 fibroblast, 371, 375, 424–425, 467
 FICZ. *See* 6-formylindolo[3,2-b]carbazole (FICZ)
 FK506, 340–342
 FK506 binding protein (FKPB), 340–341
 FKPB. *See* FK506 binding protein (FKPB)
 fludalanine, 412
 fluoroquinolones, 252, 259, 360
 flupirtine, 56–58, 63
 Food and Drug Administration (FDA), 25, 57, 113, 144, 202, 228, 240, 252, 388–389, 397, 421, 423–424, 434–436, 438–439, 441–443, 446, 451–452, 458–459, 463, 465–466, 468, 470, 482–484, 488
 6-Formylindolo[3,2-b]carbazole (FICZ), 324, 328–329
 functional selectivity, 21–22, 160, 303, 314
 FXR. *See* Farnesoid X receptor (FXR)
 FXR agonists, 70–76
 FXR/TGR5 dual agonists, 84
- Gal4 luciferase reporter assay, 92, 95
 GDC-0152, 221
 GDC-0917, 221–222
 ghrelin, 139–140, 145–148, 150, 487
 GLP-1. *See* Glucagon-like peptide-1 (GLP-1)
 glucagon-like peptide-1 (GLP-1), 70, 76–81, 84, 439, 447–448
 glucocorticoid receptor (GR), 90, 93–94, 96–99, 311, 321, 325, 341
 glucose/galactose malabsorption (GGM), 106
 glucosuria, 105–106

- glycylcyclines, 252
GPBAR1, 69
GPCR19, 69
GPCRs. *See* G-protein-coupled receptors (GPCRs)
GPR131, 69
G-protein-coupled receptors (GPCRs), 3–4, 136, 303
graft *versus* host disease, 331–332
gram-negative, 245–260, 389, 437, 453–455
GSK-962040, 141, 150
GSK-1322888, 141
GSK-894490A, 147
GSK3 β , 37, 165
guanilib, 143
guanylate cyclase, 143
GW4046, 72
- hairpin mimetics, 258–259
halaven, 227–240, 435, 465
halichondrin B, 227–240, 435, 466
halofuginone, 163
H3-antagonist, 427
HCV. *See* Hepatitis C virus (HCV)
HDAC inhibitors, 165, 371, 375, 483
heart failure, 90–93, 438
heat-shock protein (Hsp 90), 322, 341
hepatitis C virus (HCV), 42, 263–272, 274, 276, 292, 339, 345, 361–362
 core (capsid) protein inhibitors, 264–265
 entry inhibitors, 265–266
 E1 protein, 265
 E2 protein, 265
 IRES inhibitors, 274–276
 NS4A inhibitors, 267–268
 NS5A inhibitors, 270–274, 276
 NS4B inhibitors, 268–270
 p7 inhibitors, 267
hepatocytes, 265–266, 326–327, 371, 374, 377–378, 408, 424, 427
heteroaryl acetic acids, 125–126
HGS1029, 221–222
high throughput screening (HTS), 9–12, 60, 70, 97, 111, 131, 146, 148, 179–180, 193, 231, 274, 290, 311, 346, 379, 391, 394–395
2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), 328–329
hippuristanol, 201–202
HIV, 267, 285–290, 294, 303–304, 339, 344–346, 391, 396, 414, 441, 486–488
host factors, 292
hot flashes, 413
Hsp 90. *See* Heat-shock protein (Hsp 90)
5-HT_{1B} antagonist, 426
human disease, 121, 284, 329–333, 346, 354–355, 358–360, 362–363
human disease models, 369–379
5-hydroxytryptophan (5-HT), 136
hyperalgesia, 25, 27
hypertension, 90–93, 98, 438–439, 486, 491
hypokalemia, 486
- IC261, 40
ICA-27243, 55, 57, 59, 63
ICA-105665, 57, 63
IDSA. *See* Infectious Diseases Society of America (IDSA)
IL-6, 157, 159–161, 323, 327, 332, 477
IL-17, 157–159, 161–162, 327–328, 332
IL-23, 157, 159–161
IL-26, 161
ileal bile acid transporter (IBAT), 143, 150
immune homeostasis, 158
inactivated state, 22
INCB018424, 161
INCB028050, 161
indioplon, 411–412
indole acetic acids, 123–125
indoleamine dioxygenase (IDO), 327
indole sulfonamides, 98–99
induced pluripotent stem cells (iPSC), 369–379
Infectious Diseases Society of America (IDSA), 246
inflammation, 14, 90–91, 119, 121–122, 158, 161, 172, 174, 330, 339, 389, 458, 469, 480
InhA. *See* Enoyl reductase of *Mycobacterium tuberculosis* (InhA)
inhibition, 9, 20, 33–49, 74, 93, 106, 123, 145, 160, 173, 189–206, 212, 228, 266, 284, 303, 340, 360, 372, 394, 408, 422, 439
in silico, 422–424, 428
in silico screening, 125, 386, 391–392, 395–396, 398
insulin independent therapy, 104
insurmountable, 180, 303, 311–312
INT-747, 84
INT-777, 82–83
in vitro clinical trial, 374, 377–378
in vivo, 7–9, 11–13, 22, 29, 39–40, 43–45, 47, 49, 60, 62, 76–77, 80–81, 91, 97, 100, 109–112, 120, 123, 147–149, 161, 165, 173–174, 177–178, 181, 196, 198, 200, 204,

- 232, 234, 238–239, 254, 258–259, 307, 314,
324–325, 330, 333, 346, 357, 361, 372, 376,
391, 404, 408, 410–411, 414, 420–423, 426,
428, 442, 452, 454, 456, 467, 469, 472,
476–477, 483
ipragliflozin, 107–109
irreversible, 28–29, 236, 238, 303, 307–309,
311–314, 406, 413–414
ISIS-11, 274–275
ISIS-14803, 274
isotope effect, 405–406, 408
isoxicam, 394
ITE. *See* 2-(1'-H-indole-3'-carbonyl)-thiazole-
4-carboxylic acid methyl ester (ITE)
ITX-5061, 265
ITX-7650, 266
- JPE1375, 174
JSM-7717, 179
juglone, 341
- kidney damage, 97–98
kinases, 20, 26–28, 30, 35, 37–38, 40–41,
46, 49, 160, 165, 192, 198–199,
205, 217, 266, 309, 313–314,
436, 442, 469
klebsiella pneumoniae, 246
Klf4, 370–371
Kv7.1, 53–56, 59–60, 63
Kv7.2-Kv7.5, 55–62
kynurenine, 327–328
- L-AP₄, 5, 7, 12
late stage inhibitors, 249
late SV40 factor (LSF), 342
LBW-242, 216
LCL-161, 221–222
lestaurtinib, 26
leukocyte, 172, 181
ligand efficiency (LE), 40–41, 49, 162
linaclotide, 143
linezolid, 411
lipophilic efficiency (LLE), 40–41, 49
lipopolysaccharide (LPS), 122, 174, 246, 258,
323, 326–327, 394
lipoxin A₄, 332
locked nucleic acid (LNA), 355–356, 361
LPS. *See* Lipopolysaccharide (LPS)
LptD, 258
LSF. *See* Late SV40 factor (LSF)
L-SOP, 5
Lu AF21934, 8
lubiprostone, 138–139, 150
LX4211, 107–108
- M-0003, 137
M50354, 329
M50367, 330
Macaca fascicularis, 48
macrocycle, 219, 345
macrocyclic ketone, 228, 238–239
macrocyclic lactone, 231, 233–237
MAPK-interacting kinases (Mnk1), 40, 198–199
maturation inhibitors, 289–290
maximal electroshock seizure model (MES),
60–61
M-BAR, 69
MCP-1. *See* Monocyte chemotactic protein-1
(MCP-1)
M-current, 54–55, 59
MDR. *See* Multidrug-resistant (MDR)
mebudipine, 95
mechanism-based inactivator, 413
mechanism-based toxicity, 303, 310–312
membrane, 21, 54–55, 105, 122, 246, 254,
256–259, 265–268, 285, 310, 339–340, 420,
422–423, 426–427, 437, 445, 468, 495
membrane attack complex (MAC), 171,
173, 183
messenger ribonucleic acid (mRNA), 122,
175, 190–197, 199–200, 293, 324, 329, 332,
353–359, 361–362, 371
metabolic diseases, 69–85, 487
metabolic switching, 406, 408, 411
metabolism, 70, 112, 119, 137, 149, 203, 308,
346, 378, 404–406, 408, 411–413, 469, 475,
481, 487, 490, 492
metabotropic glutamate receptor (mGlu), 3–14
2'-methoxyribonucleosides, 361
7-Methylguanidine (Cap), 197–198
Met-tRNA_i, 190, 192
mGlu4, 4–5, 7–11, 13–14
mGlu6, 4–5, 11–12
mGlu7, 4–6, 12–14
mGlu8, 4, 13–14
microRNA, 351–363
microRNA sponges, 362
microtubule, 228, 341, 375, 434–435, 452,
466, 494
mineralocorticoid excess, 91
mineralocorticoid receptor (MR), 89–101
mineralocorticoid receptor antagonists, 89–101
miteminal, 141
mitochondrial stress, 339

- mitotic block, 232–235, 238, 452, 466
MK-7246, 123
MMoA. *See* Molecular mechanism of action (MMoA)
MMP1P, 14
MNAC-13, 25
modulators, 7–11, 53–63, 69–85, 98, 100, 136–137, 160, 167, 310–311, 314, 325, 376–377, 428
molecular mechanism of action (MMoA), 301–315
monocyte chemotactic protein-1 (MCP-1), 221–222
mosapride, 137
motilin, 141–142, 148–150
MP-435, 182
mRNA. *See* Messenger ribonucleic acid (mRNA)
multidrug-resistant (MDR), 246–247, 249, 251–254, 256–259
multifunctional viral protein R (Vpr), 339
multiple sclerosis (MS), 157, 274, 329, 393, 434, 441–442, 458–459, 468–470
muscarinic receptor, 305, 314, 474

naronapride, 137
National Cancer Institute (NCI), 228–231, 238–240
National Institutes of Health's Chemical Genomics Center (NCGC), 394
natural product, 46, 200–201, 228–230, 232–233, 239, 247, 254–255, 314, 434–435, 443, 452, 466, 483, 495
Nav, 20–24, 29–30
Nav1.7, 21, 23–24, 29
NCI. *See* National Cancer Institute (NCI)
negative allosteric modulator, 7–8
nerve growth factor (NGF), 20, 24–28, 30
neuraminidase (NA), 284, 314, 437, 470–472, 477–479
neurons, 26, 35, 54, 137, 142, 310, 370, 374–375, 377, 443, 495
neutrophil, 122, 129, 158, 172–174, 176, 180–182, 323, 330, 480
neutrophil chemotaxis, 339
nevirapine, 411
NF- κ B. *See* Nuclear factor kappa-light-chain-enhancer of activated (NF- κ B)
NF- κ B-inducing kinase (NIK), 217
NGD 2000-1, 178, 183
NGF. *See* Nerve growth factor (NGF)
NIK. *See* NF- κ B-inducing kinase (NIK)

NMDA receptor, 56, 310
NN8209, 182
NOD. *See* Non-obese diabetic (NOD)
noncompetitive, 178, 303, 307, 490
non-glucoside, 110–112
non-infectious virion, 292
non-obese diabetic (NOD), 223, 326, 331
non-subtype selective activator, 56
notch, 342, 372
NS5B, 263–264, 268–269, 276, 339
NSC 707389, 228
nuclear factor kappa-light-chain-enhancer of activated (NF- κ B), 216–217, 222, 323, 394–395
nuclear hormone receptor (NHR), 89, 93–94, 96–97, 99, 100, 129, 321

OC000459, 121
Oct4, 370–372
opioid, 56, 136, 139, 144, 408
Orenia[®], 164
orthosteric, 4–8, 11, 12, 302, 314
osteogenesis imperfect, 339
otelixizumab, 164
outer membrane (OM), 246, 258
overall survival, 227–240, 435, 440, 452, 461, 467, 477, 485, 486, 494
oxaboroles, 256, 259

pain, 19–30, 54–57, 59–63, 93, 143, 330, 389, 413, 437, 441, 443, 451, 464, 470, 486, 495, 496
paroxetine, 413–414
paroxysmal nocturnal hemoglobinuria (PNH), 182, 183
partial agonism, 303
parvulins, 341–342, 344, 345
patch clamp assay, 58
pateamine A, 199, 200
patient-derived, 370, 373, 375–378
patient-specific stem cell, 369
PD90780, 26
peptide mimetics, 25, 257–258
peptidyl prolyl isomerase, 337–346
period (Per), 21, 34, 35, 47–48, 137, 142, 150, 173, 182, 321, 414, 443, 456, 470, 479, 492
personalized medicine, 374, 378–379
PF-670462, 42, 48
PF-3882845, 98
PF-4457845, 28
PF-4800567, 38, 47

- PF-05089771, 23
pharmacokinetics, 23, 123, 126, 129–131, 173,
181, 182, 231–232, 257, 308, 450, 452, 474,
481, 492, 494
pharmacological selectivity, 22
Pharmacovigilance 2.0, 397–398
phase shifts, 42, 49
PHCCC, 7, 8
phenotypic screening, 390–391, 393–394
phenoxy acetic acids, 126, 129–130
phenyl acetic acids, 126–129
phosphodiesterase (PDE), 386, 408, 442,
443, 481
phospholipid, 266, 419, 420, 422–424
phospholipidosis, 419–428
Pin1, 341–342, 344–346
PKC-theta, 165
PLD. *See* Drug induced phospholipidosis
(PLD)
PMX-53, 173
polar surface area (PSA), 27, 40
positive allosteric modulator, 7–11
PPC-1807, 26
PPI, 272, 338–340, 342, 346
predictive toxicology, 377
progesterone receptor (PR), 89–90, 93–94,
96–99
PROMISCUOUS, 392
prostaglandin D₂ (PGD₂), 119–123, 126, 477
protease inhibitor, 271, 396, 410, 414
proteasome, 202, 217
protein–protein interactions, 192, 292
prucalopride, 137, 150
PS-102283, 275
pseudomonas aeruginosa, 246, 389
psychiatric, 33–49, 475
pumosetrag, 136

qRT-PCR, 355, 356
QT, 54, 373, 420–422, 492

ramatroban, 120, 121, 123, 124, 130
receptor interacting kinase (RIP1), 217
receptors, 3, 20, 35, 56, 69, 89, 120, 136, 156,
171, 196, 212, 265, 302, 321, 341, 359, 376,
391, 408, 428, 438
REGN475, 25
regulatory T (Treg) cells, 156–158, 167, 327
renal glucose reabsorption, 105, 112
renin–angiotensin aldosterone system
(RAAS), 91–93, 438
reprogramming, 369, 371, 372, 375, 379

residence time, 303, 305, 306, 311, 315
retigabine, 55–63
retinoic acid receptor-related orphan
receptor- γ t (ROR γ t), 157, 159, 161, 162,
327, 328
reverse transcriptase, 284, 288, 303
reversibility, 233–236, 238, 420, 422
reversibility ratio, 232, 234, 236, 238
ribavirin, 197, 264, 267, 269, 271
riluzole, 395
RING, 212, 218, 219
RISC. *See* RNA-induced silencing complex
(RISC)
RNA-induced silencing complex (RISC),
353, 354, 357
rofecoxib, 27, 410
ROR γ t. *See* Retinoic acid receptor-related
orphan receptor- γ t (ROR γ t)
RQ-00201894, 149
rubidium flux assay, 58, 60
Rup 43, 69

salubrinol, 202
SB-202190, 40
SB-431542, 40
SB-756050, 84
SB-791016, 146
SCH-1385145, 275
SCY-635, 345, 346
SD-254, 413
secukinumab, 158
seed match, 356, 357, 362
selective aryl hydrocarbon receptor
modulator (SAhRM), 325, 332
SGA360, 325
SGLT1, 104–108, 111
SGLT2. *See* Sodium glucose cotransporter
2 (SGLT2)
SGLT2 inhibitor, 103–113
sildenafil, 386, 388, 407–409
SIRT1, 164
Smac, 211–223
sodium glucose cotransporter 2 (SGLT2),
103–113
Soliris®, 182, 183
Sox2, 370, 371
S1P. *See* Sphingosine-1-phosphate (S1P)
sphingosine-1-phosphate (S1P), 166,
468, 469
spinal nerve ligation (SNL) model, 61
spironolactone, 90, 92–95, 97
STAT-3, 157, 159–161

- state-dependent, 21–23, 29
stem cell modulators, 376–377
stem cells, 369–379
steroid receptor, 90, 92–94
subtype selective modulator,
suprachiasmatic nucleus (SCN), 34–36, 48
synuclein, 341
systems biology, 392
- tacrolimus, 340
tail flick rat model, 62
tanezumab, 25
TAR RNA-binding protein 2 (TARBP),
353, 360
tau (τ), 34, 341, 342, 375
Taxol[®], 221, 240, 434, 452, 467
tegaserod, 137, 150
telaprevir, 264, 269, 410–411
telomere maintenance, 342
teplizumab, 164
terfenadine, 266
ternary complex, 190–192, 202–205, 311,
339, 340
tetracyclines, 251–252
TGR5, 69, 70, 77, 78, 82–84
TGR5 agonists, 70, 76–84
Th17, 155–167, 333
thalidomide, 388
thallium flux assay, 58
Th17 cells, 157–159, 162, 327, 328
thiozolidone-indenones, 203–204
thymidylate synthase (TS), 342
TL32711, 221–223
TLR7, 166
TNF α . *See* Tumor necrosis factor alpha (TNF α)
TNF α receptor-associated factor (TRAF),
217, 218
TNF α -related apoptosis-inducing ligand
(TRAIL), 196, 216, 223
tocilizumab, 159
tofogliflozin, 107, 108
tolperisone, 412–413
torsades, 421, 492
torsadogen, 421
total synthesis, 228, 230–231, 239, 240,
345, 483
TRAIL. *See* TNF α -related apoptosis-
inducing ligand (TRAIL)
tramadol, 408–410
transformation, 59, 190–192, 194
Treg. *See* Regulatory T (Treg) cells
Trk, 26, 27
TrkA, 20, 24–28, 30
TS-071, 107, 108, 110, 112
tubulin, 196, 451, 452, 465–467, 493, 494
tumor necrosis factor alpha (TNF α), 165, 216,
217, 222, 223, 309, 323, 330, 394,
464, 477
TWEAK, 223
type-2 chloride channel (ClC-2), 138–139
type 2 diabetes, 70, 84, 100, 103–113, 203, 331,
359, 375, 439, 446–448
TZP-102, 140, 150
- ubiquitin, 36, 196, 212, 213, 217, 219
UGE. *See* Urinary glucose excretion (UGE)
ulimorelin, 139, 140, 150
uncompetitive, 303, 310
3' untranslated region (3'UTR), 356, 357
urinary albumin, 98
urinary glucose excretion (UGE), 105,
109–112
use-dependent, 23
3'UTR. *See* 3' untranslated region (3'UTR)
uveitis, 158, 332
- VAF347, 328
VAG539, 330
vasculitis, 172, 181, 182
velusetrag, 137
venlafaxine, 413
voltage-sensitive domain (VSD), 54, 55
Vpr. *See* Multifunctional viral protein R (Vpr)
VSD. *See* Voltage-sensitive domain (VSD)
VU0155041, 10
- W-54011, 176, 177
WAY169916, 325
- xenograft, 196, 198, 200, 201, 203, 220,
232, 494
xenograft model, 200, 203, 205, 222, 232–234,
236, 238, 452, 467
- Y1036, 26
- zebrafish, 390, 391, 393
zeitgebers, 34, 43, 48